425 related articles for article (PubMed ID: 17919490)
1. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Vanwolleghem T; Meuleman P; Libbrecht L; Roskams T; De Vos R; Leroux-Roels G
Gastroenterology; 2007 Oct; 133(4):1144-55. PubMed ID: 17919490
[TBL] [Abstract][Full Text] [Related]
2. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
Reiser M; Hinrichsen H; Benhamou Y; Reesink HW; Wedemeyer H; Avendano C; Riba N; Yong CL; Nehmiz G; Steinmann GG
Hepatology; 2005 Apr; 41(4):832-5. PubMed ID: 15732092
[TBL] [Abstract][Full Text] [Related]
3. A twenty-eight-day mechanistic time course study in the rhesus monkey with hepatitis C virus protease inhibitor BILN 2061.
Stoltz JH; Stern JO; Huang Q; Seidler RW; Pack FD; Knight BL
Toxicol Pathol; 2011 Apr; 39(3):496-501. PubMed ID: 21441227
[TBL] [Abstract][Full Text] [Related]
4. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
[TBL] [Abstract][Full Text] [Related]
5. Novel robust hepatitis C virus mouse efficacy model.
Zhu Q; Oei Y; Mendel DB; Garrett EN; Patawaran MB; Hollenbach PW; Aukerman SL; Weiner AJ
Antimicrob Agents Chemother; 2006 Oct; 50(10):3260-8. PubMed ID: 17005803
[TBL] [Abstract][Full Text] [Related]
6. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.
Meuleman P; Leroux-Roels G
Antiviral Res; 2008 Dec; 80(3):231-8. PubMed ID: 18706933
[TBL] [Abstract][Full Text] [Related]
7. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor.
Kamiya N; Iwao E; Hiraga N; Tsuge M; Imamura M; Takahashi S; Miyoshi S; Tateno C; Yoshizato K; Chayama K
J Gen Virol; 2010 Jul; 91(Pt 7):1668-77. PubMed ID: 20164258
[TBL] [Abstract][Full Text] [Related]
8. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
9. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera.
Meuleman P; Libbrecht L; De Vos R; de Hemptinne B; Gevaert K; Vandekerckhove J; Roskams T; Leroux-Roels G
Hepatology; 2005 Apr; 41(4):847-56. PubMed ID: 15791625
[TBL] [Abstract][Full Text] [Related]
10. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections.
Kosaka K; Hiraga N; Imamura M; Yoshimi S; Murakami E; Nakahara T; Honda Y; Ono A; Kawaoka T; Tsuge M; Abe H; Hayes CN; Miki D; Aikata H; Ochi H; Ishida Y; Tateno C; Yoshizato K; Sasaki T; Chayama K
Biochem Biophys Res Commun; 2013 Nov; 441(1):230-5. PubMed ID: 24140055
[TBL] [Abstract][Full Text] [Related]
11. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
[TBL] [Abstract][Full Text] [Related]
12. Virology: fresh assault on hepatitis C.
Rice CM
Nature; 2003 Nov; 426(6963):129-31. PubMed ID: 14578912
[No Abstract] [Full Text] [Related]
13. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.
Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M
Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643
[TBL] [Abstract][Full Text] [Related]
14. Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.
Mo H; Yang C; Wang K; Wang Y; Huang M; Murray B; Qi X; Sun SC; Deshpande M; Rhodes G; Miller MD
J Viral Hepat; 2011 May; 18(5):338-48. PubMed ID: 20456634
[TBL] [Abstract][Full Text] [Related]
15. Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061.
Herrmann E; Zeuzem S; Sarrazin C; Hinrichsen H; Benhamou Y; Manns MP; Reiser M; Reesink H; Calleja JL; Forns X; Steinmann GG; Nehmiz G
Antivir Ther; 2006; 11(3):371-6. PubMed ID: 16759054
[TBL] [Abstract][Full Text] [Related]
16. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
[TBL] [Abstract][Full Text] [Related]
17. Development of humanized mice for the study of hepatitis C virus infection.
Turrini P; Sasso R; Germoni S; Marcucci I; Celluci A; Di Marco A; Marra E; Paonessa G; Eutropi A; Laufer R; Migliaccio G; Padron J
Transplant Proc; 2006 May; 38(4):1181-4. PubMed ID: 16757300
[TBL] [Abstract][Full Text] [Related]
18. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
19. Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice.
Vanwolleghem T; Libbrecht L; Hansen BE; Desombere I; Roskams T; Meuleman P; Leroux-Roels G
J Hepatol; 2010 Sep; 53(3):468-76. PubMed ID: 20591528
[TBL] [Abstract][Full Text] [Related]
20. Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application.
Kneteman NM; Weiner AJ; O'Connell J; Collett M; Gao T; Aukerman L; Kovelsky R; Ni ZJ; Zhu Q; Hashash A; Kline J; Hsi B; Schiller D; Douglas D; Tyrrell DL; Mercer DF
Hepatology; 2006 Jun; 43(6):1346-53. PubMed ID: 16729319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]